Gefitinib Recruiting Phase 2 Trials for EGFR Mutations / Metastatic Brain Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

RecruitingTreatment2 IdentifierTitleDrugs
NCT01951469Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer
NCT03374280Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC
NCT03944772Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
NCT02804776PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
NCT03267654Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
NCT02856893Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)